Upper urinary tract instillations in the treatment of urothelial carcinomas: A review of technical constraints and outcomes

World Journal of Urology

Volumn 31, Issue 1, 2013, Pages 45-52

  Audenet, François ^a   Traxer, Olivier ^b   Bensalah, Karim ^c   Rouprêt, Morgan ^d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL TENON   (France)

^c Academic Department of Urology of Rennes Pontchaillou   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Adjuvant therapy; Bacillus Calmette Gu rin (BCG); Mitomycin C; Recurrence; Renal pelvis; Upper urinary tract; Ureter; Urothelial carcinomas

Indexed keywords

EID: 84873119276     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0949-3     Document Type: Article

References (52)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi: 10. 3322/caac. 20138.
2. Huffman JL (1988) Ureteroscopic management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 15: 419-424.
3. Vest SA (1945) Conservative surgery in certain benign tumors of the ureter. J Urol 53: 97-120.
4. Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183: 2148-2153. doi: 10. 1016/j. juro. 2010. 02. 005.
5. Chen GL, Bagley DH (2000) Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 164: 1173-1176.
6. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59: 584-594. doi: 10. 1016/j. eururo. 2010. 12. 042.
7. Cornu JN, Roupret M, Carpentier X, Geavlete B, de Medina SG, Cussenot O et al (2010) Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 28: 151-156. doi: 10. 1007/s00345-009-0494-x.
8. Keeley FX Jr, Bibbo M, Bagley DH (1997) Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 157: 1560-1565.
9. Johnson GB, Fraiman M, Grasso M (2005) Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int 95(Suppl 2): 110-113.
10. Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al (2011) Oxford Centre for Evidence-Based Medicine. The Oxford 2011 levels of evidence. http://www. cebm. net/index. aspx?o=5653.
11. Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA (2005) A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 95: 791-793. doi: 10. 1111/j. 1464-410X. 2005. 05402. x.
12. Sylvester RJ, van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970. doi: 10. 1097/01. ju. 0000034450. 80198. 1c.
13. Huncharek M, McGarry R, Kupelnick B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21: 765-769.
14. O'Donoghue JP, Crew JP (2004) Adjuvant topical treatment of upper urinary tract urothelial tumours. BJU Int 94: 483-485. doi: 10. 1111/j. 1464-410X. 2004. 04987. x.
15. van Helsdingen PJ, Rikken CH (1986) Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop. J Urol 136: 461-463.
16. Eastham JA, Huffman JL (1993) Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol 150: 324-325.
17. Keeley FX Jr, Bagley DH (1997) Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol 158: 2074-2077.
18. Orihuela E, Smith AD (1988) Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 15: 425-431.
19. De Kock ML, Breytenbach IH (1986) Local excision and topical thiotepa in the treatment of transitional cell carcinoma of the renal pelvis: a case report. J Urol 135: 566-567.
20. Katz MH, Lee MW, Gupta M (2007) Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourol 21: 374-377; discussion 377 doi: 10. 1089/end. 2007. 9969.
21. Herr HW (1985) Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol 134: 531-532.
22. Sharpe JR, Duffy G, Chin JL (1993) Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol 149: 457-459; discussion 459-460.
23. Ramsey JC, Soloway MS (1990) Instillation of bacillus Calmette-Guerin into the renal pelvis of a solitary kidney for the treatment of transitional cell carcinoma. J Urol 143: 1220-1222.
24. Mukamel E, Layfield LJ, Hawkins RA, Dekernion JB (1988) The effect of bacillus Calmette-Guerin on the urinary system of pigs. J Urol 139: 165-169.
25. Smith AD, Orihuela E, Crowley AR (1987) Percutaneous management of renal pelvic tumors: a treatment option in selected cases. J Urol 137: 852-856.
26. Studer UE, Casanova G, Kraft R, Zingg EJ (1989) Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. J Urol 142: 975-977.
27. Thalmann GN, Markwalder R, Walter B, Studer UE (2002) Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 168: 1381-1385.
28. Rastinehad AR, Ost MC, Vanderbrink BA, Greenberg KL, El-Hakim A, Marcovich R et al (2009) A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology 73: 27-31. doi: 10. 1016/j. urology. 2008. 06. 026.
29. Huang A, Low RK, White deVere R (1995) Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma. J Urol 153: 1041-1042.
30. Irie A, Iwamura M, Kadowaki K, Ohkawa A, Uchida T, Baba S (2002) Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 59: 53-57.
31. Yossepowitch O, Lifshitz DA, Dekel Y, Ehrlich Y, Gur U, Margel D et al (2005) Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 173: 890-893. doi: 10. 1097/01. ju. 0000147747. 89028. 64.
32. Patel A, Fuchs GJ (1998) New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol 159: 71-75.
33. Rastinehad AR, Smith AD (2009) Bacillus Calmette-Guerin for upper tract urothelial cancer: is there a role? J Endourol 23: 563-568. doi: 10. 1089/end. 2008. 0164.
34. Schneider B, Thanhauser A, Jocham D, Loppnow H, Vollmer E, Galle J et al (1994) Specific binding of bacillus Calmette-Guerin to urothelial tumor cells in vitro. World J Urol 12: 337-344.
35. Jarrett TW, Sweetser PM, Weiss GH, Smith AD (1995) Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol 154: 1629-1635.
36. Schoenberg MP, van Arsdalen KN, Wein AJ (1991) The management of transitional cell carcinoma in solitary renal units. J Urol 146: 700-702; discussion 702-703.
37. Vasavada SP, Streem SB, Novick AC (1995) Definitive tumor resection and percutaneous bacille Calmette-Guerin for management of renal pelvic transitional cell carcinoma in solitary kidneys. Urology 45: 381-386.
38. Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L (1996) Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 156: 377-385.
39. Clark PE, Streem SB, Geisinger MA (1999) 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol 161: 772-775; discussion 775-776.
40. Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE (2011) Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 60: 955-960. doi: 10. 1016/j. eururo. 2011. 07. 051.
41. Jabbour ME, Smith AD (2000) Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 27: 739-750.
42. Kojima Y, Tozawa K, Kawai N, Sasaki S, Hayashi Y, Kohri K (2006) Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guerin therapy. Int J Urol 13: 340-344. doi: 10. 1111/j. 1442-2042. 2006. 01312. x.
43. Audenet F, Traxer O, Yates DR, Cussenot O, Roupret M (2012) Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU Int 109: 608-613; discussion 613-604 doi: 10. 1111/j. 1464-410X. 2011. 10363. x.
44. Traxer O, Geavlete B, de Medina SG, Sibony M, Al-Qahtani SM (2011) Narrow-band imaging digital flexible ureteroscopy in detection of upper urinary tract transitional-cell carcinoma: initial experience. J Endourol 25: 19-23. doi: 10. 1089/end. 2009. 0593.
45. O'Brien T, Ray E, Singh R, Coker B, Beard R (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60: 703-710. doi: 10. 1016/j. eururo. 2011. 05. 064.
46. Nishino Y, Yamamoto N, Komeda H, Takahashi Y, Deguchi T (2000) Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int 85: 799-801.
47. Bellman GC, Sweetser P, Smith AD (1994) Complications of intracavitary bacillus Calmette-Guerin after percutaneous resection of upper tract transitional cell carcinoma. J Urol 151: 13-15.
48. Yokogi H, Wada Y, Mizutani M, Igawa M, Ishibe T (1996) Bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol 77: 676-679.
49. Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Nishimura K et al (2000) Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 38: 701-704; discussion 705.
50. Okubo K, Ichioka K, Terada N, Matsuta Y, Yoshimura K, Arai Y (2001) Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int 88: 343-347.
51. Miyake H, Eto H, Hara S, Okada H, Kamidono S, Hara I (2002) Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Int J Urol 9: 677-680.
52. Hayashida Y, Nomata K, Noguchi M, Eguchi J, Koga S, Yamashita S et al (2004) Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology 63: 1084-1088. doi: 10. 1016/j. urology. 2004. 01. 046.